恩杂鲁胺治疗化疗后晚期去势抵抗性前列腺癌：意大利患者项目。
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
机构信息
Medical Oncology, S Chiara Hospital, Largo Medaglie d'Oro 1, Trento, Italy.
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.
出版信息
Future Oncol. 2018 Nov;14(26):2691-2699. doi: 10.2217/fon-2018-0113. Epub 2018 Sep 12.
AIM
To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results.
PATIENTS & METHODS: Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14.8% had received both.
RESULTS
Median progression-free survival and overall survival were 4.8 and 13.1 months, respectively. A prostate-specific antigen reduction ≥50% was observed in 49.1%. Total 32.7% abiraterone-pretreated patients achieved a biochemical response compared with 56% of abiraterone-naive patients.
CONCLUSION
Enzalutamide was safe and well tolerated. Its antitumor activity in abiraterone-pretreated patients was limited.
目的
为了收集多西他赛治疗后的恩扎卢胺的疗效和安全性数据，我们回顾性评估了意大利患者项目的结果。
患者与方法
209 例转移性去势抵抗性前列腺癌患者入组。中位年龄为 73 岁。总 42.1%的患者有疼痛，14.4%的患者体能状态为 2 分，59.8%的患者 Gleason 评分为≥8 分。总 31.1%的患者之前接受过≥2 种化疗，分别有 15.3%和 12%的患者之前接受过阿比特龙和卡巴他赛治疗，14.8%的患者同时接受过这两种治疗。
结果
中位无进展生存期和总生存期分别为 4.8 个月和 13.1 个月。分别有 49.1%和 32.7%的患者观察到前列腺特异性抗原（PSA）降低≥50%和≥30%。与阿比特龙初治患者相比，阿比特龙预处理患者中有 56%获得了生化缓解。
结论
恩扎卢胺是安全且耐受良好的。它在阿比特龙预处理患者中的抗肿瘤活性有限。
Zotero 插件